Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03132740
Other study ID # 201702
Secondary ID
Status Recruiting
Phase
First received April 5, 2017
Last updated April 17, 2018
Start date March 15, 2017
Est. completion date June 1, 2019

Study information

Verified date March 2018
Source Zhujiang Hospital
Contact Fang Chihua, M.D.;Ph.D
Phone +8613609700805
Email fangch_dr@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the multi-centre study is to evaluate correctly the impact of three dimensional visualization on operation strategy and complications for complex hepatic carcinoma.


Description:

Because of the complexity of complex hepatic carcinoma,the limitations of 2D images of CT/MRI and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2D imaging(CT/MRI).The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for complex hepatic carcinoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date June 1, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. 18 years= Age =70 years

2. Compling with the diagnosis criteria of complex hepatic carcinoma.

3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled

4. Preoperative liver function is Child - Pugh grade A or B.

5. The patients are volunteered for the study.

Exclusion Criteria:

1. Patients with mental illness.

2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)

3. The patients refused to take part in the study.

4. There are other co-existed malignant tumors.

5. Benign liver diseases.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Zhujiang Hospital of The Southern Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact on operation strategy of three dimensional visualization technique Firstly, the operation strategies based on original CT or MRI image data will be made by the team, Secondly, the operation strategies based on three dimensional reconstruction models will be made by the team, then, actually surgical strategies will be recorded. The change of operation strategy will be assessed by comparing the strategy of the 2D model and 3D model. The change rate of operation strategy will be recorded and presented as percentage. 2 year
Primary Impact on complication of three dimensional visualization technique The complications are refer to the classification of Clavien-Dindo, including postoperative bleeding, biliary fistula, ascites, postoperative liver failure, renal dysfunction, pleural effusion, abdominal cavity infection, abdominal abscess, incision infection, the occurrence cases of each complication (number) will be recorded. 2 year
Secondary Blood routine examination (the 1th, 3 th, 5th, 7th) Hemoglobin (g/L), Platelet(109/L), and neutrophilic granulocyte percentage (%) 2 year
Secondary Urine routines (the 1th, 3 th,5th, 7th) Urine specific gravity, urine protein(mg/dl), urine sugar(mmol/L), leukocytes in urine(number/ul), urine erythrocyte(number/ul) 2 year
Secondary Stool Routine (the 1th, 3 th,5th, 7th) Defecate occult blood test, Microorganisms (mold, parasites, etc.) 2 year
Secondary Blood biochemistry (the 1th, 3 th,5th, 7th) Serum albumin(g/L), serum pre-albumin(g/L), serum globulin(g/L), total bilirubin(µmol/L), direct bilirubin(µmol/L),serum glutamic-oxaloacetic transaminase (AST, IU/L), serum glutamic pyruvic transaminase (ALT, IU/L), alkaline phosphatase (ALP, IU/L), gamma glutamyl transpeptidase(r-GGT, IU/L) ,Serum creatinine(µmol/L), Urea(mmol/L), Blood sugar(mmol/L) 2 year
Secondary Tumor marker Alpha fetoprotein(AFP, ng/L), Carbohydrate antigen-199(CA-199, ku/L), Carbohydrate antigen-125(CA-125, ku/L), Carcinoembryonic antigen (CEA, ng/L), Carbohydrate antigen-153(CA-153, ku/L) 2 year
Secondary The blood coagulation function (the 1th, 3th, 5th, 7th) prothrombin time (PT, s), partial thromboplastin time (APTT), international normalized ratio (INR), plasma prothrombin activity (PTA, %), fibrinogen (FIB, g/L), d—dimer(mg/L) 2 year
Secondary Inflammatory biomarkers C-reactive protein, procalcitonin 2 year
Secondary Preoperative viral loading HBV- DNA?HCV- RNA 2 year
Secondary Postoperative results of paraffin wax and immunohistochemical index AFP?Ki67?CK18?CK19?Hepatocyte 2 year
See also
  Status Clinical Trial Phase
Recruiting NCT03253250 - The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection Phase 4
Terminated NCT01760616 - Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy Phase 4
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Not yet recruiting NCT03149523 - Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors N/A
Recruiting NCT05009550 - ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation N/A
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Completed NCT03164382 - Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma Phase 3
Completed NCT03572582 - Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Phase 2
Completed NCT04266548 - Arterial Base Fluorescence Segmental Positive Staining N/A
Recruiting NCT03013712 - A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer Phase 1/Phase 2
Recruiting NCT01350726 - Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan N/A
Completed NCT06245798 - Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Recruiting NCT06311396 - Development of a Neuronal Microscope N/A
Recruiting NCT04220944 - Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. Phase 1
Completed NCT02352935 - Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function N/A
Completed NCT02332551 - Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder N/A
Completed NCT02834780 - Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Phase 1
Not yet recruiting NCT06182865 - A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy N/A
Completed NCT05007548 - to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve Phase 2
Completed NCT03163186 - Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). N/A